SEARCH

Current Edition

clinical trial

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could …

Continue Reading →